Anofer - Injection Elemental Iron (Iron iii Hydroxide Sucrose Complex) - 100mg/5ml 1 5ml ampoule(s) / 5ml ampoule Monicopharma Limited Introduction: Anofer is an iron replacement product. It is used to treat a type of anemia where you have too few red blood cells because you have too little iron in your body (iron-deficiency anaemia). Iron is needed to produce the red blood cells that carry oxygen around your body. Anofer is given as injection by your doctor or nurse. You will be watched carefully to make sure you do not have an allergic reaction. Your doctor will decide how much dose you need depending on the cause of your anaemia, it may help to eat a well-balanced diet that has... Uses of Anofer: Iron deficiency anemiaAnemia due to chronic kidney disease Side effects of Anofer: Injection site reactions (pain, swelling, redness)NauseaDark colored stool How to use Anofer: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Anofer works: Anofer is an anti-anemic medication. It replenishes the iron stores in your body. Iron is vital for the formation of new red blood cells and hemoglobin, a substance that gives these cells the ability to transport oxygen. What if you forget to take Anofer?: If you miss a dose of Anofer, please consult your doctor. Indication: Iron deficiency anemia, in pregnancy and in non-dialysis dependent chronic kidney disease (CKD) patients, hemodialysis dependent CKD patients or peritoneal dialysis CKD patients Administration: Before administering a slow intravenous injection, a test dose of 1 ml (20 mg of iron) should be injected slowly over a period of 1 to 2 minutes. If no adverse events occur within 15 minutes of completing the test dose, then the remaining portion of the injection may be given. As injection: Iron Sucrose can also be administered undiluted by slow IV injection at a rate of 1 ml Iron Sucrose (20 mg Iron) in at least 1 minute a maximum of 10 ml Iron Sucrose (200 mg Iron) can be administered per injection in at least 10 minutes.... Adult Dose: Adults and the Elderly: Iron-deficiency Anemia in Chronic Kidney Disease Hemodialysis-dependent CKD: 100 mg elemental iron IV (injection or infusion over 2-5 min) per dialysis session not to exceed total cumulative dose of 1000 mg divided in 3 doses/week Non-dialysis-dependent CKD: 200 mg IV injection for 5 doses in over 14 days (cumulative 1000 mg in 14-day period) Peritoneal dialysis-dependent CKD: 300 mg IV infusion (1.5 hr) for 2 doses 14 days apart, THEN 400 mg IV infusion (2.5 hr) 14 days later (cumulative 1000 mg divided in 3 doses/week) Child Dose: Iron-deficiency Anemia in Chronic Kidney Disease Indicated for maintenance treatment of iron-deficient anemia associated with chronic kidney disease <2 years: Safety and efficacy not established Hemodialysis-dependent: 0.5 mg/kg IV q2weeks for 12 weeks; not to exceed 100 mg/dose Non-dialysis dependent or peritoneal-dependent (on erythropoietin): 0.5 mg/kg IV q4weeks for 12 weeks; not to exceed 100 mg/dose Contraindication: The use of Iron Sucrose is contraindicated in patients with evidence of Iron overload e.g. Haemochromatosis, thalassemia or haemosiderosis and in patients with known hypersensitivity to Iron preparations or any components preparation, in patients with anemia not caused by Iron deficiency. Mode of Action: Iron: Essential component in the formation of hemoglobin; adequate amounts of iron are necessary for effective erythropoiesis; also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin. Precaution: Iron Sucrose should be administered with caution in patients with asthma, eczema, other atopic allergies or allergic reaction to other parenteral Iron preparations, low binding capacity and/or folic acid deficiency, liver dysfunction, acute or chronic infection. Baseline tests: Ensure Hgb, Hct, serum ferritin and transferrin saturation is determined before starting therapy and periodically during treatment. Note that serum Iron levels may be reliably obtained 48 hours after IV dosing. Blood Pressure: Monitor Blood Pressure during infusion. If hypotension occurs, slow the rate of infusion. If hypotension continues, discontinue infusion and be prepared to treat appropriately. Discontinue oral Iron preparations before... Side Effect: >10% Hypotension (36%),Muscle cramps (23%),Headache,Nausea 1-10% Dizziness,Fatigue,Arthralgia,Back pain,Hypertension,Fluid overload,Peripheral edema,Cough,Vomiting,Diarrhea,Constipation,Pruritus Frequency Not Defined Potentially fatal anaphylaxis (rare) Pregnancy Category Note: Pregnancy Published studies on intravenous iron sucrose treatment after first trimester of pregnancy not shown adverse maternal or fetal outcomes; available reports of intravenous iron sucrose use in pregnant women during first trimester are insufficient to assess risk of major birth defects and miscarriage; iron deficiency anemia during pregnancy should be treated because there are risks to mother and fetus associated with untreated iron deficiency anemia (IDA) in pregnancy Animal data Animal reproduction studies of iron sucrose administered to rats and rabbits during period of organogenesis at elemental iron doses equivalent to maximum recommended human dose based on body surface... Interaction: May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine. Potentially Fatal: Dimercaprol may increase the nephrotoxic effect of iron salts when used concurrently.